• Je něco špatně v tomto záznamu ?

Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L

AS. Ashhurst, AH. Tang, P. Fajtová, MC. Yoon, A. Aggarwal, MJ. Bedding, A. Stoye, L. Beretta, D. Pwee, A. Drelich, D. Skinner, L. Li, TD. Meek, JH. McKerrow, V. Hook, CT. Tseng, M. Larance, S. Turville, WH. Gerwick, AJ. O'Donoghue, RJ. Payne

. 2022 ; 65 (4) : 2956-2970. [pub] 20211103

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010939

Grantová podpora
U01 TW006634 FIC NIH HHS - United States

Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC50 values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells and, together with two lead analogues, potently inhibited SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range. Reduced antiviral activity was observed in cells overexpressing transmembrane protease, serine 2 (TMPRSS2); however, a synergistic improvement in antiviral activity was achieved when combined with a TMPRSS2 inhibitor. These data highlight the potential of cathepsin L as a COVID-19 drug target as well as the likely need to inhibit multiple routes of viral entry to achieve efficacy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010939
003      
CZ-PrNML
005      
20220506130538.0
007      
ta
008      
220425s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.1c01494 $2 doi
035    __
$a (PubMed)34730959
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ashhurst, Anneliese S $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia $u School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW2006, Australia
245    10
$a Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L / $c AS. Ashhurst, AH. Tang, P. Fajtová, MC. Yoon, A. Aggarwal, MJ. Bedding, A. Stoye, L. Beretta, D. Pwee, A. Drelich, D. Skinner, L. Li, TD. Meek, JH. McKerrow, V. Hook, CT. Tseng, M. Larance, S. Turville, WH. Gerwick, AJ. O'Donoghue, RJ. Payne
520    9_
$a Cathepsin L is a key host cysteine protease utilized by coronaviruses for cell entry and is a promising drug target for novel antivirals against SARS-CoV-2. The marine natural product gallinamide A and several synthetic analogues were identified as potent inhibitors of cathepsin L with IC50 values in the picomolar range. Lead molecules possessed selectivity over other cathepsins and alternative host proteases involved in viral entry. Gallinamide A directly interacted with cathepsin L in cells and, together with two lead analogues, potently inhibited SARS-CoV-2 infection in vitro, with EC50 values in the nanomolar range. Reduced antiviral activity was observed in cells overexpressing transmembrane protease, serine 2 (TMPRSS2); however, a synergistic improvement in antiviral activity was achieved when combined with a TMPRSS2 inhibitor. These data highlight the potential of cathepsin L as a COVID-19 drug target as well as the likely need to inhibit multiple routes of viral entry to achieve efficacy.
650    _2
$a buňky A549 $7 D000072283
650    _2
$a zvířata $7 D000818
650    _2
$a kationické antimikrobiální peptidy $x chemická syntéza $x chemie $x farmakologie $7 D023181
650    _2
$a antivirové látky $x chemická syntéza $x chemie $x farmakologie $7 D000998
650    _2
$a biologické přípravky $x chemická syntéza $x chemie $x farmakologie $7 D001688
650    _2
$a COVID-19 $x metabolismus $7 D000086382
650    _2
$a kathepsin L $x antagonisté a inhibitory $x metabolismus $7 D056668
650    _2
$a Cercopithecus aethiops $7 D002522
650    _2
$a inhibitory cysteinových proteinas $x chemická syntéza $x chemie $x farmakologie $7 D015853
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a lidé $7 D006801
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a molekulární konformace $7 D008968
650    _2
$a proteomika $7 D040901
650    _2
$a SARS-CoV-2 $x účinky léků $7 D000086402
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a Vero buňky $7 D014709
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Tang, Arthur H $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia
700    1_
$a Fajtová, Pavla $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610Prague, Czech Republic
700    1_
$a Yoon, Michael C $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States $1 https://orcid.org/0000000229005257
700    1_
$a Aggarwal, Anupriya $u Kirby Institute, University of New South Wales, Sydney, NSW2052, Australia
700    1_
$a Bedding, Max J $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia
700    1_
$a Stoye, Alexander $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia
700    1_
$a Beretta, Laura $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
700    1_
$a Pwee, Dustin $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
700    1_
$a Drelich, Aleksandra $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas77755-1001, United States
700    1_
$a Skinner, Danielle $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
700    1_
$a Li, Linfeng $u Department of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas77843, United States $1 https://orcid.org/0000000161854999
700    1_
$a Meek, Thomas D $u Department of Biochemistry and Biophysics, Texas A&M University, 301 Old Main Drive, College Station, Texas77843, United States $1 https://orcid.org/0000000219318073
700    1_
$a McKerrow, James H $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
700    1_
$a Hook, Vivian $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
700    1_
$a Tseng, Chien-Te $u Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas77755-1001, United States
700    1_
$a Larance, Mark $u Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW2006, Australia $1 https://orcid.org/0000000285792267
700    1_
$a Turville, Stuart $u Kirby Institute, University of New South Wales, Sydney, NSW2052, Australia
700    1_
$a Gerwick, William H $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States $u Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California San Diego, La Jolla, California92093, United States
700    1_
$a O'Donoghue, Anthony J $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California92093, United States
700    1_
$a Payne, Richard J $u School of Chemistry, The University of Sydney, Sydney, NSW2006, Australia $u Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, NSW2006, Australia $1 https://orcid.org/0000000236189226
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 65, č. 4 (2022), s. 2956-2970
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34730959 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130530 $b ABA008
999    __
$a ok $b bmc $g 1788856 $s 1162137
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 65 $c 4 $d 2956-2970 $e 20211103 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
GRA    __
$a U01 TW006634 $p FIC NIH HHS $2 United States
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace